MATINAS BIOPHARMA HOLDINGS, INC. (OTCMKTS:MTNB) Files An 8-K Regulation FD Disclosure
Item 7.01
| Regulation FD Disclosure. |
On June 26, 2017, Matinas BioPharma Holdings, Inc. (the Company)
issued a press release to report topline data from its Phase 2
safety, tolerability and efficacy study of MAT2203 in women with
moderate to severe vulvovaginal candidiasis (VVC). The press
release is attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the
information in this Item 7.01 of this Current Report on Form 8-K,
including Exhibit 99.1, shall not be deemed filed for the
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Exchange Act or the
Securities Act of 1933, as amended, except as shall be expressly
set forth by specific reference in such a filing.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | ExhibitNo. | Description. | ||
| 99.1 | Press Release, dated June 26, 2017. |
Matinas BioPharma Holdings, Inc. ExhibitEX-99.1 2 v469602_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Matinas BioPharma Reports Topline Data from Phase 2 Clinical Study of Orally-Administered MAT2203 for the Treatment of Vulvovaginal Candidiasis – Management to host conference call today,…To view the full exhibit click here About MATINAS BIOPHARMA HOLDINGS, INC. (OTCMKTS:MTNB)
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections. Its cochleate delivery technology platform is designed for the targeted delivery of pharmaceuticals directly to the site of infection or inflammation. Its MAT 2203 is an oral formulation of a spectrum anti-fungal drug called amphotericin B, which uses its cochleate delivery technology. Its MAT2501 is an orally administered, encochleated formulation of the spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including non-tubercular mycobacterial infections (NTM), as well as various multidrug-resistant gram negative and intracellular bacterial infections.
